KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Receivables - Net: 2009-2024

Historic Receivables - Net for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $308.5 million.

  • Halozyme Therapeutics' Receivables - Net rose 21.10% to $346.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $346.0 million, marking a year-over-year increase of 21.10%. This contributed to the annual value of $308.5 million for FY2024, which is 31.70% up from last year.
  • As of FY2024, Halozyme Therapeutics' Receivables - Net stood at $308.5 million, which was up 31.70% from $234.2 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Receivables - Net ranged from a high of $308.5 million in FY2024 and a low of $92.1 million during FY2021.
  • Its 3-year average for Receivables - Net is $257.9 million, with a median of $234.2 million in 2023.
  • Its Receivables - Net has fluctuated over the past 5 years, first decreased by 6.70% in 2021, then spiked by 150.85% in 2022.
  • Halozyme Therapeutics' Receivables - Net (Yearly) stood at $98.7 million in 2020, then declined by 6.70% to $92.1 million in 2021, then soared by 150.85% to $231.1 million in 2022, then climbed by 1.36% to $234.2 million in 2023, then spiked by 31.70% to $308.5 million in 2024.